Amgen’s Mvasi Biosimilar Overtakes Avastin In The US

California-Based Giant Enjoyed Biosimilars Sales Of $1.7bn Last Year

 
• By Dean Rudge
AMGEN_1174421407_1200.jpg
Amgen has just launched its fifth biosimilar in the US, a rival to rituximab. • Source: Amgen

More from Biosimilars

More from Products